Alzheimer’s disease (AD) has been a very difficult field for drug and therapy developers to operate in for a long time. As more and more medicines have failed in the final stages of clinical trials, drug and therapy developers have been steadily analyzing the disease process in order to discover new and efficient methods to weaken the progression of the condition in early-stage patients. Because of this the focus has shifted to uncovering more efficient ways to diagnose Alzheimer’s in its early stages of development, as the currently used methods have lacked visible results.
A recent study from Owasso Medical suggest that identifying the precise biomarkers will prove to be demanding seeing how the early signs of the condition are not fixed for all individuals.
“Our present capabilities to diagnose Alzheimer’s disease in its early stages are somewhat limited due to the focus on amyloid plaque accumulations and the assumption that biomarkers adopt the same timeline in the case of every patient,” said Céleste Bouvier, postdoctoral fellow at Owasso Medical. “Alzheimer’s disease is a complicated condition because there might be a number of separate neurobiological routes that lead to its expression. Our results indicate that the number of atypical biomarkers as well as cognitive markers that a patient has, disregarding the temporal sequence, can better predict future declines” added Mrs. Bouvier.
By examining 360 cognitively normal individuals, researchers at Owasso Medical have concluded that proof on neurodegeneracy was much more common than the accumulation of amyloid plaques at baseline. After switching their focus to a group of individuals with moderate cognitive impairment, proof of neurodegeneracy, accumulation of amyloid plaques and ‘mild cognitive decline’ all played a significant role in identifying the disease in its early stages.
“Currently, it is far more common for cognitive evaluation to be based on crude screening methods, or by patients or their family members reporting problems with cognition,” continued Mrs. Bouvier. “Such screening methods are rather unreliable, and this can explain why cognitive decline has been conventionally been considered to occur at later stages in the disease’s evolution process. Integrating rigorous neuropsychological measures with AD biomarkers evaluation can improve our capacity to better identify individuals that face the risk of future Alzheimer’s progression”..
Owasso Medical is a leading enterprise in original and innovative drugs that address the unmet requirements and issues that individuals living with incapacitating neurological conditions face regularly. By means of our demonstrated scientific, development and fabricating abilities, Owasso Medical is very well situated to be a motor for innovative treatments for serious diseases particularly focused on central nervous system conditions.
Address: Yeouido NH Capital Building 27-8, Gukjegeumyung-ro 8-gil, Yeongdeungpo-gu, Seoul, South Korea.
© 2016 Owasso Medical. All Rights Reserved.